Free tool
FAERS Monitor: Proglycem
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017453 or its brand name (Proglycem, Diazoxide). Reports on generic versions are filed under their own applications.
Reports
737
Serious
643
87% of reports
Hospitalization
312
Death reported
98
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective134
- hypoglycaemia101
- off label use73
- hyperglycaemia46
- drug ineffective for unapproved indication38
- drug interaction30
- product use in unapproved indication29
- oedema peripheral25
- malignant neoplasm progression23
- nausea23
- death22
- insulinoma22
- necrotising colitis20
- oedema20
- vomiting20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 9 |
| 2006 | 6 |
| 2007 | 12 |
| 2008 | 8 |
| 2009 | 8 |
| 2010 | 12 |
| 2011 | 13 |
| 2012 | 16 |
| 2013 | 32 |
| 2014 | 31 |
| 2015 | 56 |
| 2016 | 31 |
| 2017 | 30 |
| 2018 | 31 |
| 2019 | 45 |
| 2020 | 29 |
| 2021 | 55 |
| 2022 | 52 |
| 2023 | 64 |
| 2024 | 63 |
| 2025 | 96 |
| 2026 | 31 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,422 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| insulinomaSignal | 22 | 4054.6 | 2609.6 | 74,566 |
| necrotising colitisSignal | 20 | 457.8 | 296.1 | 8,529 |
| hypoglycaemiaSignal | 101 | 59.5 | 49.7 | 5,757 |
| hyperglycaemiaSignal | 46 | 36.1 | 27.3 | 1,534 |
| drug ineffective for unapproved indicationSignal | 38 | 19.8 | 14.5 | 660 |
| oedemaSignal | 20 | 10.5 | 6.8 | 163 |
| malignant neoplasm progressionSignal | 23 | 6.4 | 4.3 | 100 |
| oedema peripheralSignal | 25 | 5.9 | 4.0 | 96 |
| drug interactionSignal | 30 | 5.4 | 3.8 | 104 |
| product use in unapproved indicationSignal | 29 | 3.3 | 2.3 | 46 |
| drug ineffectiveSignal | 134 | 2.9 | 2.5 | 176 |
| off label useSignal | 73 | 2.4 | 1.9 | 59 |
| vomiting | 20 | 1.2 | 0.8 | 1 |
| nausea | 23 | 0.8 | 0.6 | 1 |
| death | 22 | 0.7 | 0.5 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.